Today's free PANCE question, with a full explanation

Disclosure: Alma publishes this article and makes one of the study tools it discusses.

Pending clinician review: The question and explanation on this page are draft content and will be reviewed by a clinician before publication.

If you want one solid PANCE-style check in your day, this page is for you. Below is today’s free PANCE question of the day, written to the NCCPA blueprint format and tagged by organ system and task area.^[1] After you answer it, you will see a detailed explanation and a one-line takeaway you can turn into a flashcard.

Over time, this page will grow into an archive of daily PANCE questions by organ system, so you can revisit systems you keep missing. If you use a spaced repetition tool, you can keep today’s key fact in long-term review instead of letting it disappear.

Today's PANCE question

Organ system: Cardiovascular
Task area: Pharmaceutical therapeutics

A 64-year-old man with ischemic cardiomyopathy comes to the clinic for a routine follow-up visit. For the past 6 months he has had stable dyspnea when climbing one flight of stairs, two-pillow orthopnea, and occasional paroxysmal nocturnal dyspnea. He has hypertension and does not have diabetes mellitus. Current medications are lisinopril 20 mg daily, metoprolol succinate 200 mg daily, furosemide 40 mg daily, aspirin 81 mg daily, and atorvastatin 40 mg daily. Blood pressure is 118/72 mm Hg and pulse is 62/min and regular. Examination shows an S3 gallop, clear lungs, and trace bilateral ankle edema. ECG shows normal sinus rhythm. Serum potassium is 4.4 mEq/L, hemoglobin A1c is 5.6%, and estimated glomerular filtration rate is 58 mL/min/1.73 m². An echocardiogram last month showed a left ventricular ejection fraction of 30%.

Which of the following additional medications is most appropriate to reduce this patient’s risk of cardiovascular death and heart failure hospitalization?

1. Digoxin
2. Hydrochlorothiazide
3. Diltiazem
4. Sodium-glucose cotransporter-2 (SGLT2) inhibitor
5. Ivabradine

Answer and explanation below. Pick your answer (1 to 5) before you read past this line.

---

Correct answer: 4. Sodium-glucose cotransporter-2 (SGLT2) inhibitor

Explanation and key takeaway

Why option 4 is correct

This patient has symptomatic chronic heart failure with reduced ejection fraction (HFrEF), indicated by a left ventricular ejection fraction of 40% or less (30% in this patient), dyspnea, orthopnea, paroxysmal nocturnal dyspnea, peripheral edema, and an S3 gallop.^[2] For patients with HFrEF due to left ventricular dysfunction, guideline-directed medical therapy includes angiotensin receptor–neprilysin inhibitors or ACE inhibitors, beta blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors to reduce morbidity and mortality.^[3][2] In symptomatic chronic HFrEF, an SGLT2 inhibitor (dapagliflozin or empagliflozin, 10 mg once daily) is a Class 1 recommendation to reduce heart failure hospitalization and cardiovascular mortality, irrespective of type 2 diabetes.^[2] This patient already takes an ACE inhibitor and a beta blocker at target dose, so the SGLT2 inhibitor adds a missing foundational class. A mineralocorticoid receptor antagonist is the other missing class, but it is not among the options.

Why the other options are incorrect

Option 1: Digoxin
Digoxin is sometimes used in heart failure to help control symptoms, but current guideline-directed medical therapy emphasizes other classes such as angiotensin receptor–neprilysin inhibitors, beta blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors as foundational for HFrEF. ^[3] Digoxin did not reduce mortality in the DIG trial, and the 2022 AHA/ACC/HFSA guideline gives it only a Class 2b recommendation to decrease heart failure hospitalizations in patients who remain symptomatic despite guideline-directed therapy.^[2] Therefore, digoxin is not the best next step for optimizing guideline-directed therapy in this stable patient.

Option 2: Hydrochlorothiazide
Thiazide diuretics may be used for hypertension and mild fluid overload, but they are not part of the core mortality-reducing regimen in HFrEF.^[3][2] Loop diuretics, like this patient’s furosemide, are typically preferred in symptomatic volume overload, and adding a thiazide would address symptoms rather than significantly alter long-term cardiovascular outcomes.^[2]

Option 3: Diltiazem
Diltiazem and verapamil are nondihydropyridine calcium channel blockers with negative inotropic effects. In HFrEF they can worsen heart failure, and the 2022 AHA/ACC/HFSA guideline lists them as not recommended (Class 3: Harm).^[2] Diltiazem would add risk without any outcome benefit for this patient.

Option 5: Ivabradine
Ivabradine slows the sinus rate by inhibiting the funny current (If) in the sinoatrial node. It is a Class 2a option to reduce heart failure hospitalization and cardiovascular death only in stable, symptomatic HFrEF with a left ventricular ejection fraction of 35% or less, sinus rhythm, and a resting heart rate of 70/min or higher despite a beta blocker at the maximum tolerated dose.^[2] This patient has a resting heart rate of 62/min on target dose metoprolol succinate, so he does not meet those criteria, and SGLT2 inhibitors carry the stronger Class 1 recommendation.

Key takeaway
In symptomatic chronic HFrEF, once a patient is on appropriate ACE inhibitor or angiotensin receptor–neprilysin inhibitor, evidence-based beta blocker, and diuretics as needed, adding an SGLT2 inhibitor is a guideline-directed step that reduces cardiovascular death and heart failure hospitalizations, regardless of diabetes status.^[3][2]

Blueprint tags

Reference used for this explanation
The explanation above is based on contemporary descriptions of heart failure epidemiology, classification, and therapy, as well as recommendations that HFrEF management include ACE inhibitors or angiotensin receptor–neprilysin inhibitors, beta blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors to improve outcomes.^[3][2]

How can I keep today's question in my review?

To make today’s learning stick, capture the core fact as a spaced repetition card. In a tool like Alma’s Flashcards, you can quickly create a card with the clinical scenario on the front and the answer on the back, then review it over time using spaced repetition.

For example:

• Front: “In symptomatic chronic HFrEF already on an ACE inhibitor, beta blocker, and loop diuretic, which additional class of medication is part of guideline-directed medical therapy to further reduce heart failure risk?” ^[3]
• Back: “Add an SGLT2 inhibitor (dapagliflozin or empagliflozin) as part of guideline-directed foundational therapy. If no MRA is on board, that is the other missing foundational class.”

Each time the card comes up, force yourself to retrieve the class name and its purpose before flipping. Over days to weeks, the intervals between reviews grow, so you can keep HFrEF pillars clear without rereading guidelines constantly.

Past PANCE questions by organ system

New questions will be added under each organ system below as they are published, so this section will become a browsable index of past questions. The systems follow the current NCCPA PANCE content blueprint, effective January 2025, which sorts medical content into these 14 organ systems plus professional practice.^[1] That way, when you realize cardiovascular or pulmonary questions keep tripping you up, you can drill those systems directly. These organ system categories mirror how the NCCPA allocates questions across content areas in the PANCE blueprint, helping you see where your practice is concentrated.^[1] For each system’s share of the exam and a topic checklist, see the PANCE blueprint explained.

How to get the most out of one PANCE question a day

One question a day will not replace a full Qbank, but it can anchor a powerful recall habit if you work it deliberately. Treat each question as both a knowledge check and a trigger to connect facts back to the PANCE blueprint and your own notes, not just as a quick guess.

Here is a practical way to use this page:

1. Answer it cold. Before peeking at the explanation, commit to an answer and, ideally, write down a one-sentence justification. This mimics test conditions and reveals real gaps.
2. Explain the concept aloud. After reading the explanation, teach the core idea back to yourself or a study partner. For today’s item, that might be walking through the pillars of guideline-directed HFrEF therapy and when SGLT2 inhibitors are added.^[3][2]
3. Turn misses into cards. Any detail you missed or guessed becomes a flashcard in your system of choice. If you are using Alma’s flashcards, your reviews are one of the signals behind Alma Insights, which estimates the topics that stay weak for you over time.
4. Connect to the blueprint. Quickly map each question to its organ system and task area so you are always thinking in exam categories, just as the PANCE blueprint does with content and task allocations.^[1]

For a more complete strategy that combines daily recall with higher-volume practice, see how AI study tools and Qbanks fit together in PANCE prep, and our comparison of the best AI study tools for PA school students.

Frequently asked questions

Are these real PANCE questions?

No. These are original practice questions written for this page. They are informed by publicly available NCCPA PANCE content blueprints, which describe how PANCE questions are allocated to medical content and task categories, but they are not taken from the actual PANCE, PANRE, or any retired NCCPA item bank. ^[1]

Who writes and reviews the PANCE question of the day?

Each question and explanation is original and drafted with AI assistance. Every clinical statement is checked against a current guideline cited in the explanation (for today’s question, the 2022 AHA/ACC/HFSA heart failure guideline and the 2024 ACC decision pathway for HFrEF), and a clinician (physician or PA-C) reviews the question before it goes live. ^[3][2]

Reviewed by: [Reviewer name, credentials] on [review date] (placeholder: fill in after clinician review, before publishing)

How is this different from a full PANCE Qbank?

A full Qbank gives you hundreds or thousands of questions so you can accumulate pattern recognition, timing practice, and broad content exposure. A daily PANCE question like this is much lighter in volume, but it is built to support consistency and deep explanation: you answer, then spend time understanding why each option is right or wrong and embedding the takeaway in a card.

Used together, a Qbank provides the bulk exposure, while the daily question maintains a low-friction habit of retrieval and explanation even on busy days. The organ system and task tags help you stay oriented to the blueprint while you do it.^[1]

How closely do these questions follow the NCCPA PANCE format?

The questions are written to follow the broad structure described by the NCCPA: single-best-answer multiple-choice questions^[5], mapped to content categories like cardiovascular or pulmonary systems and task areas such as pharmaceutical therapeutics, clinical intervention, or history-taking.^[1] However, they are not official NCCPA items, and they should be used alongside, not instead of, the NCCPA’s own materials.

Is one daily PANCE question enough for exam prep?

No. The PANCE is a 300-question computer-based exam covering multiple organ systems and task categories, administered in timed blocks.^[4] One question a day is a helpful supplement for recall and habits, but effective preparation also requires higher-volume question practice, targeted content review, and timed sessions that simulate the full test environment.

Use this page to keep at least one exam-style decision in your mind each day, while your main study plan relies on comprehensive resources, systematic blueprint coverage, and timed practice blocks. If you want one-on-one help on top of that, see when an AI PANCE tutor fits and when to hire a person.

If you want one place to keep takeaways like today’s in review, Alma builds FSRS flashcards and quizzes from your own notes and estimates which topics stay weak for you. It is a study tool, not a Qbank, so use it alongside one. Alma has a 1-week free trial; after that it costs $20 a month or $180 a year.

References

1. NCCPA: PANCE Content Blueprint (effective January 2025)
2. Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145(18)
3. Maddox TM, et al. 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2024;83(15)
4. NCCPA: PANCE Test Day
5. NCCPA: Item Writing Workshop (NCCPA exams use multiple-choice, one-best-answer items)